Atrial Fibrillation (AF) Clinical Trial
Official title:
Smartphone-based KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation: A Pilot Study
This is a two-center, randomized controlled trial of 100 patients comparing intervention (KardiaMobile) with standard of care. Kardia Mobile is an FDA approved device that allows one- or six lead ECG recording for 30 seconds using the patient's smart phone. The device has a automated algorithm that interprets the ECG as either sinus rhythm, AF, or unclassified. The intervention arm will be given a KardiaMobile device, free of charge, to be synched to their smartphone at the time of enrollment. They will be instructed on proper device procedure and will use the device with the onset of potential AF-related symptoms (e.g. chest pressure, palpitations, lightheadedness, syncope, shortness of breath, or other symptoms concerning for a cardiac etiology) or when requested to do so by their healthcare provider. The device ECG recordings will be transmitted to participants physicians through MyChart who will incorporate this information into the patient's treatment as indicated. All files will be stored on a private, secure platform and any subsequent communication from the clinical team will occur via standard clinical channels (MyChart or telephone contact). Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02630914 -
Medical and Surgical Hybrid Treatment of Atrial Fibrillation.
|
N/A | |
Completed |
NCT05410379 -
Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
|
||
Completed |
NCT04025710 -
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
|
N/A | |
Completed |
NCT01119274 -
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon
|
Phase 4 | |
Recruiting |
NCT03428048 -
Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
|
||
Recruiting |
NCT04298723 -
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
|
N/A | |
Completed |
NCT04218266 -
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
|
Phase 2 | |
Active, not recruiting |
NCT03732794 -
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
|
N/A | |
Active, not recruiting |
NCT04755283 -
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT04095559 -
Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
|
||
Recruiting |
NCT05712200 -
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
|
Phase 3 | |
Recruiting |
NCT05955365 -
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
|
Phase 4 | |
Recruiting |
NCT05294445 -
From the Emergency Department Directly to Ablation of Atrial Fibrillation Study
|
N/A | |
Completed |
NCT02513316 -
Clinical Relevance of Microbleeds In Stroke
|
N/A | |
Completed |
NCT04809922 -
Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation
|